PR:000001193beta-2 adrenergic receptorCL:0000192smooth muscle cellUBERON:0001135smooth muscle tissueD007889leiomyomaGO:0031698beta-2 adrenergic receptor bindingGO:0004941beta2-adrenergic receptor activityGO:0044557relaxation of smooth muscleGO:0008283cell proliferationD006984hypertrophy1increased10090CD-1 mouse10116SD ratActivation, beta-2 adrenergic receptorActivation, beta-2 adrenergic receptorMolecularCL:0000255eukaryotic cell2016-11-29T18:41:282017-09-16T10:17:04Increased activity, beta-2 adrenergic receptorIncreased activity, beta-2 adrenergic receptorMolecularCL:0000255eukaryotic cell2016-11-29T18:41:282017-09-16T10:17:04relaxation, smooth musclerelaxation, smooth muscleTissue2016-11-29T18:41:282016-12-03T16:37:52Proliferation/Clonal Expansion, smooth muscleProliferation/Clonal Expansion, smooth muscleCellularCL:0000192smooth muscle cell2016-11-29T18:41:282017-09-16T10:17:04Hypertrophy/hyperplasia, smooth muscleHypertrophy/hyperplasia, smooth muscleCellular2016-11-29T18:41:282016-12-03T16:37:52Promotion, mesovarian leiomyomasPromotion, mesovarian leiomyomasTissueUBERON:0000995uterus2016-11-29T18:41:282017-09-16T10:17:05d08433ae-94da-4bb9-80f3-220be3869d6c5a9ec2a8-251a-41d6-b33e-aa10a6527fe92016-11-29T18:41:362016-12-03T16:38:035a9ec2a8-251a-41d6-b33e-aa10a6527fe98cc58bf8-c2b6-4373-af1b-6f110c8921922016-11-29T18:41:362016-12-03T16:38:038cc58bf8-c2b6-4373-af1b-6f110c892192ba376467-6f85-4da3-8662-b7245d762c482016-11-29T18:41:362016-12-03T16:38:03ba376467-6f85-4da3-8662-b7245d762c484a432f0a-8ce0-47a4-a064-1dd52c7ed20a2016-11-29T18:41:362016-12-03T16:38:034a432f0a-8ce0-47a4-a064-1dd52c7ed20a6a8544fb-5a32-407f-b586-a91bb49334ac2016-11-29T18:41:362016-12-03T16:38:03Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouseBeta-2 adrenergic agonist induction of mesovarian leiomyomas<p>Cancer AOP Workgroup. National Health and Environmental Effects Research Laboratory, Office of Research and Development, Integrated Systems Toxicology Division, US Environmental Protection Agency, Research Triangle Park, NC. Corresponding author for wiki entry (wood.charles@epa.gov)</p>
Under Development: Contributions and Comments WelcomeUnder Development1.29<p>This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.</p>
adjacentNot SpecifiedHighadjacentNot SpecifiedHighadjacentNot SpecifiedHighnon-adjacentNot SpecifiedHighnon-adjacentNot SpecifiedHighHighFemaleHighHigh<p>1. Gibson, J. P., Sells, D. M., Cheng, H. C., and Yuh, L. (1987). Induction of uterine leiomyomas in mice by medroxalol and prevention by propranolol. Toxicologic pathology 15(4), 468-73.</p>
<p>2. Gopinath, C., and Gibson, W. A. (1987). Mesovarian leiomyomas in the rat. Environmental health perspectives 73, 107-13.</p>
<p> </p>
2016-11-29T18:41:172023-04-29T16:02:58